These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 3378354)

  • 41. Does the Administration of Sevelamer or Nicotinamide Modify Uremic Toxins or Endotoxemia in Chronic Hemodialysis Patients?
    Lenglet A; Fabresse N; Taupin M; Gomila C; Liabeuf S; Kamel S; Alvarez JC; Drueke TB; Massy ZA
    Drugs; 2019 Jun; 79(8):855-862. PubMed ID: 31062264
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Influence of uremic toxins and nonesterified fatty acids on drug and thyroid hormone binding in serum.
    Lim CF; Stockigt JR
    Clin Chem; 1998 Nov; 44(11):2380-1. PubMed ID: 9799777
    [No Abstract]   [Full Text] [Related]  

  • 43. Effects of uremic serum and uremic toxins on hepatic uptake of digoxin.
    Tsujimoto M; Kinoshita Y; Hirata S; Otagiri M; Ohtani H; Sawada Y
    Ther Drug Monit; 2008 Oct; 30(5):576-82. PubMed ID: 18708994
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cooperative inhibitory effects of uremic toxins and other serum components on OATP1B1-mediated transport of SN-38.
    Katsube Y; Tsujimoto M; Koide H; Ochiai M; Hojyo A; Ogawa K; Kambara K; Torii N; Shima D; Furukubo T; Izumi S; Yamakawa T; Minegaki T; Nishiguchi K
    Cancer Chemother Pharmacol; 2017 Apr; 79(4):783-789. PubMed ID: 28314987
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Association of advanced age with concentrations of uraemic toxins in CKD.
    Rroji M; Eloot S; Dhondt A; Van Biesen W; Glorieux G; Neirynck N; Vandennoortgate N; Liabeuf S; Massy Z; Vanholder R
    J Nephrol; 2016 Feb; 29(1):81-91. PubMed ID: 25857296
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Separation of albumin-binding ligands present in uremic serum by high-performance affinity chromatography.
    Mabuchi H; Nakahashi H
    J Chromatogr; 1990 Aug; 529(2):424-30. PubMed ID: 2229260
    [No Abstract]   [Full Text] [Related]  

  • 47. Effects of uremic toxins and fatty acids on serum protein binding of furosemide: possible mechanism of the binding defect in uremia.
    Takamura N; Maruyama T; Otagiri M
    Clin Chem; 1997 Dec; 43(12):2274-80. PubMed ID: 9439444
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Protein-bound uremic solutes: the forgotten toxins.
    Vanholder R; De Smet R; Lameire N
    Kidney Int Suppl; 2001 Feb; 78():S266-70. PubMed ID: 11169024
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Composite Uremic Load and Physical Performance in Hemodialysis Patients: A Cross-Sectional Study.
    Vanden Wyngaert K; Van Craenenbroeck AH; Holvoet E; Calders P; Van Biesen W; Eloot S
    Toxins (Basel); 2020 Feb; 12(2):. PubMed ID: 32098304
    [TBL] [Abstract][Full Text] [Related]  

  • 50. In vitro Removal of Protein-Bound Retention Solutes by Extracorporeal Blood Purification Procedures.
    Schildboeck C; Harm S; Hartmann J
    Blood Purif; 2024; 53(4):231-242. PubMed ID: 38262384
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Removal of protein-bound uraemic toxins by haemodialysis.
    Niwa T
    Blood Purif; 2013; 35 Suppl 2():20-5. PubMed ID: 23676831
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Protein-bound uremic retention solutes.
    Brunet P; Dou L; Cerini C; Berland Y
    Adv Ren Replace Ther; 2003 Oct; 10(4):310-20. PubMed ID: 14681860
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Exploring binding characteristics and the related competition of different protein-bound uremic toxins.
    Deltombe O; de Loor H; Glorieux G; Dhondt A; Van Biesen W; Meijers B; Eloot S
    Biochimie; 2017 Aug; 139():20-26. PubMed ID: 28528271
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Plasma clearance in the rat of a furan dicarboxylic acid which accumulates in uremia.
    Costigan MG; Lindup WE
    Kidney Int; 1996 Mar; 49(3):634-8. PubMed ID: 8648903
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Study by means of high-performance liquid chromatography of solutes that decrease theophylline/protein binding in the serum of uremic patients.
    De Smet R; Vogeleere P; Van Kaer J; Lameire N; Vanholder R
    J Chromatogr A; 1999 Jun; 847(1-2):141-53. PubMed ID: 10431358
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Accumulation of quinolinic acid in uremic serum and its removal by hemodialysis.
    Niwa T; Yoshizumi H; Emoto Y; Miyazaki T; Hashimoto N; Takeda N; Tatematsu A; Maeda K
    Clin Chem; 1991 Feb; 37(2):159-61. PubMed ID: 1825184
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Diminished protein binding capacity of uremic sera for valproate following hemodialysis: role of free fatty acids and uremic compounds.
    Dasgupta A; Jacques M; Malhotra D
    Am J Nephrol; 1996; 16(4):327-33. PubMed ID: 8739287
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Recent progress in the analysis of uremic toxins by mass spectrometry.
    Niwa T
    J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Sep; 877(25):2600-6. PubMed ID: 19083276
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A major endogenous ligand substance involved in renal failure.
    Mabuchi H; Nakahashi H
    Nephron; 1988; 49(4):277-80. PubMed ID: 3412543
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Phenol and p-cresol accumulated in uremic serum measured by HPLC with fluorescence detection.
    Niwa T
    Clin Chem; 1993 Jan; 39(1):108-11. PubMed ID: 8419031
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.